Islande - islandais - LYFJASTOFNUN (Icelandic Medicines Agency)

williams & halls ehf.* - rivaroxabanum inn - filmuhúðuð tafla - 10 mg

Islande - islandais - LYFJASTOFNUN (Icelandic Medicines Agency)

accord healthcare b.v. - mycophenolatum natríum - magasýruþolin tafla - 180 mg

Islande - islandais - LYFJASTOFNUN (Icelandic Medicines Agency)

accord healthcare b.v. - mycophenolatum natríum - magasýruþolin tafla - 360 mg

Islande - islandais - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - hydrochlorothiazidum inn; losartanum kalíum - filmuhúðuð tafla - 100/25 mg

Islande - islandais - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - losartanum kalíum; hydrochlorothiazidum inn - filmuhúðuð tafla - 50/12,5 mg

Islande - islandais - LYFJASTOFNUN (Icelandic Medicines Agency)

bluefish pharmaceuticals ab - letrozolum inn - filmuhúðuð tafla - 2,5 mg

Union européenne - islandais - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cystic fibrosis - Önnur öndunarfæri - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

Islande - islandais - LYFJASTOFNUN (Icelandic Medicines Agency)

bluefish pharmaceuticals ab - simvastatinum inn - filmuhúðuð tafla - 40 mg

Islande - islandais - LYFJASTOFNUN (Icelandic Medicines Agency)

williams & halls ehf - letrozolum inn - filmuhúðuð tafla - 2,5 mg

Islande - islandais - LYFJASTOFNUN (Icelandic Medicines Agency)

bluefish pharmaceuticals ab - simvastatinum inn - filmuhúðuð tafla - 10 mg